Intravitreal Dexamethasone implant injection: Analysis of clinical efficacy and subjective satisfaction of patients with post-thrombotic macular edema
https://doi.org/10.34215/1609-1175-2020-3-93-94
Abstract
Objective: Analysis of clinical efficacy and subjective satisfaction of patients with post-thrombotic macular edema after intravitreal administration of Ozurdex (dexamethasone).
Methods: Thestudy included 33 patients (33 eyes) aged from 51 to 75 years with post-thrombotic macular retinal edema. The results were assessed before the intravitreal implantation, after one day, after a month, and three months later after the surgery.
Results: The central retinal thickness significantly decreased on the first day after the surgery remaining almost the same after one and three months. The average retinal thickness had the similar dynamics. The macular volume reduced by 1.5 times in a day after the surgery. The maximum corrected visual acuity gradually increased over the time, remaining on average at the level of 0.5 diopters after one and three months. The subjective evalua‑ tion of quality of life (according to the VF-14 questionnaire) during the observation period progressively increased reaching 47.1 points by the end of the study.
Conclusions: The study findings convincingly indicate the clinical efficacy of the intravitreal administration of dexamethasone and the subjective satisfaction of patients with the quality of treatment both in the early and late postoperative periods.
About the Authors
K. V. Sokolov
Primorskiy Center of Eye Microsurgery
Russian Federation
Russian Federation
MD, PhD,
100e Borisenko St., Vladivostok, 690080
A. K. Smirnov
Primorskiy Center of Eye Microsurgery
Russian Federation
Russian Federation
MD,
100e Borisenko St., Vladivostok, 690080
References
1. Badazhkov EG, Kulagina AV, Kucher EG. Analysis of the clinical efficacy of the complex treatment of post-thrombotic and retinopathy using the intravitreal use of the drug “Osurdex” and laser retinal coagulation. Modern Technologies in Ophthalmology. 2015;2:92 (In Russ).
2. Perevozchikov PA, Komissarov AV, Ivanova KV. The experience of using the drug Ozurdex in the complex treatment of retinal vein thrombosis with edema of the macular zone. Modern Technologies in Ophthalmology. 2017;1:216–9 (In Russ).
3. Artemyeva OV, Samoilov AN, Zhernakov SV. Description of the clinical experience of the drug Ozurdex. RMJ Clinical Ophthalmology. 2013;3:104–8 (In Russ).
4. Burkholder BM, Moradi A, Thorne JE, Dunn JP. The dexamethasone intravitreal implant for noninfectious uveitis: Practice patterns among uveitis specialists. Ocul Immunol Inflamm. 2015;23(6):444–53.
5. Nobre-Cardoso J, Champion E, Darugar A, Fel A, Lehoang Ph, Bodaghi B. Treatment of noninfectious uveitic macular edema with the intravitreal Dexamethasone implant. Ocul Immunol Inflamm. 2016;25(4):447–54.
6. Steinberg EP, Tielsch JM, Schein OD, Javitt JC, Sharkey P, Cassard SD, et al. The VF-14. An index of functional impairment in patients with cataract. Arch Ophthalmol. 1994;112(5):630–8.
Review
For citations:
Sokolov K.V., Smirnov A.K. Intravitreal Dexamethasone implant injection: Analysis of clinical efficacy and subjective satisfaction of patients with post-thrombotic macular edema. Pacific Medical Journal. 2020;(3):93-94. (In Russ.) https://doi.org/10.34215/1609-1175-2020-3-93-94
Views:
439
Email this article 